In the 1990s, some physicians believed drugmakers’ assurances that prescription opioids wouldn't cause patients with pain to develop substance use disorders.
They were tragically misguided.
How did that happen? How can such public health disasters be prevented going forward?
The August issue of the AMA Journal of Ethics, dedicated to the underlying ethical questions of the opioid epidemic, offers up potential solutions.
- A call for future research to focus on improving prevention strategies and population-based programs
- An exploration of how the FDA enabled aggressive marketing of opioids and how correcting these regulatory missteps can prevent future public health crises
- 5 best practices for pharmacist-physician collaborations on pain management
- What health professions students should know about the undue influence of drug and device marketing on their practices—and how to better protect patients